Preclinical and clinical applications of specific molecular imaging for HER2-positive breast cancer.

Wei Chen, Xiaofeng Li, Lei Zhu, Jianjing Liu, Wengui Xu, Ping Wang,


Cancer biology & medicine, September 8, 2017


Precision medicine and personalized therapy are receiving increased attention, and molecular-subtype classification has become crucial in planning therapeutic schedules in clinical practice for patients with breast cancer. Human epidermal growth factor receptor 2 (HER2) is associated with high-grade breast tumors, high rates of lymph-node involvement, high risk of recurrence, and high resistance to general chemotherapy. Analysis of HER2 expression is highly important for doctors to identify patients who can benefit from trastuzumab therapy and monitor the response and efficacy of treatment. In recent years, significant efforts have been devoted to achieving specific and noninvasive HER2-positive breast cancer imaging in vivo. In this work, we reviewed existing literature on HER2 imaging in the past decade and summarized the studies from different points of view, such as imaging modalities and HER2-specific probes. We aimed to improve the understanding on the translational process in molecular imaging for HER2 breast cancer.


Pubmed Link: 28884043

DOI: 10.20892/j.issn.2095-3941.2017.0044